Pathway presented final data from its pivotal, multi-center European clinical trial for its first-generation device, the Pathway PV atherectomy system at TCT 2008. The company also presented interim study data for its next-generation device
The data, presented by Dr Thomas Zeller, Bad Krozingen, Germany and co-principal investigator of Pathway’s clinical trials, demonstrate the safety and efficacy of Pathway’s atherectomy catheter for the treatment of peripheral artery disease (PAD) in the lower limbs.
Pathway’s President and CEO Paul Buckman said, “Since receiving FDA clearance for the Jetstream Atherectomy Catheter in September, we have experienced tremendous interest in the technology from clinicians interested not only in minimally invasive treatment options for PAD patients.”
